# Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

> **NCT05004675** · PHASE3 · COMPLETED · sponsor: **LIB Therapeutics LLC** · enrollment: 166 (actual)

## Conditions studied

- Hypercholesterolemia
- Atherosclerotic Ischemic Disease

## Interventions

- **BIOLOGICAL:** lerodalcibep
- **DRUG:** Inclisiran

## Key facts

- **NCT ID:** NCT05004675
- **Lead sponsor:** LIB Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-20
- **Primary completion:** 2024-05-30
- **Final completion:** 2024-10-15
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2024-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05004675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05004675, "Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05004675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*